| Apertura: | - |
| Variazione: | - |
| Volumi: | - |
| Minimo: | - |
| Massimi: | - |
| Distanza Mas/Min: | - |
| Tipologia: | Azioni |
| Ticker: | CMRX |
| ISIN: |
Chimerix to Present at the 35th Annual J.P. Morgan Healthcare Conference
- 58
DURHAM, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering and developing medicines that improve outcomes for immunocompromised patients, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 8:30 a.m. PT (11:30 a.m. ET) at the Westin Saint Francis Hotel in San Francisco, CA.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at http://ir.chimerix.com/events.cfm, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering and developing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage compounds. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Will O’Connor Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
GlobeNewswire è una delle più grandi reti di distribuzione di newswire al mondo, specializzata nella distribuzione di comunicati stampa aziendali, informazioni finanziarie e contenuti multimediali a media, investitori e lettori di tutto il mondo.
